title: Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence.
abstract: The effects of the polypeptide hormone prolactin (PRL) in the development and regulation of benign prostate hyperplasia (BPH) and also in prostate cancer are not very well characterized. This study examines the action of PRL, either alone or in association with androgens [testosterone (T) or dihydrotestosterone (DHT)], in the rat prostate gland. The effects of PRL and androgens were investigated after 30 and 60 days in control, castrated, castrated with a substitutive implant of T or DHT, and sham-operated Wistar rats. To enhance PRL release, we induced hyperprolactinemia by administering chronic injections of sulpiride (40 mg. kg(-1). day(-1)). Chronic hyperprolactinemia induces enlargement and inflammation of the lateral rat prostate without any histological changes on ventral and dorsal lobes. We also demonstrate that hyperprolactinemia induces Bcl-2 overexpression in the lateral rat prostate and that this could inhibit the level of apoptosis. The in vivo model established here is a useful in vivo approach for studying the hormonal regulation of normal and pathological prostate development.
authors: Laboratoire de Physiologie Cellulaire, Institut National de la Santé et de la Recherche Médicale (INSERM) EPI-9938, 59655 Villeneuve d'Ascq, France. fvancopp@pop.univ-lille1.fr
authors: F
authors: F
authors: Van Coppenolle
authors: C
authors: C
authors: Slomianny
authors: F
authors: F
authors: Carpentier
authors: X
authors: X
authors: Le Bourhis
authors: A
authors: A
authors: Ahidouch
authors: D
authors: D
authors: Croix
authors: G
authors: G
authors: Legrand
authors: E
authors: E
authors: Dewailly
authors: S
authors: S
authors: Fournier
authors: H
authors: H
authors: Cousse
authors: D
authors: D
authors: Authie
authors: J P
authors: JP
authors: Raynaud
authors: J C
authors: JC
authors: Beauvillain
authors: J P
authors: JP
authors: Dupouy
authors: N
authors: N
authors: Prevarskaya
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D002908:Chronic Disease; D013196:Dihydrotestosterone / Q000097:blood / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology; D012739:Gonadal Steroid Hormones / Q000097:blood / Q000494:pharmacology*; D006966:Hyperprolactinemia / Q000139:chemically induced / Q000473:pathology*; D008297:Male; D009919:Orchiectomy; D009929:Organ Size; D011388:Prolactin / Q000097:blood; D011467:Prostate / Q000254:growth & development* / Q000378:metabolism / Q000473:pathology*; D011470:Prostatic Hyperplasia / Q000139:chemically induced / Q000473:pathology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis; D051381:Rats; D017208:Rats, Wistar; D013469:Sulpiride / Q000494:pharmacology; D013739:Testosterone / Q000097:blood / Q000494:pharmacology*
chemical_list: D018492:Dopamine Antagonists; D012739:Gonadal Steroid Hormones; D019253:Proto-Oncogene Proteins c-bcl-2; D013196:Dihydrotestosterone; D013739:Testosterone; D013469:Sulpiride; D011388:Prolactin